Dr. Eng on Ongoing Studies for BRAF-Mutant CRC

Cathy Eng, MD
Published: Wednesday, Jan 03, 2018



Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing trials investigating treatment for patients with BRAF-mutant colorectal cancer (CRC).

The SWOG 1406 trial looked at a control arm of irinotecan and cetuximab (Erbitux) plus or minus vemurafenib (Zelboraf) with a primary endpoint of progression-free survival (PFS). The study was positive for PFS, but there was crossover allowed, so it was not positive for overall survival, explains Eng.

According to Eng, it was an eye-opening study as it provided a BRAF inhibitor to patients as part of a clinical trial.
 
SELECTED
LANGUAGE


Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing trials investigating treatment for patients with BRAF-mutant colorectal cancer (CRC).

The SWOG 1406 trial looked at a control arm of irinotecan and cetuximab (Erbitux) plus or minus vemurafenib (Zelboraf) with a primary endpoint of progression-free survival (PFS). The study was positive for PFS, but there was crossover allowed, so it was not positive for overall survival, explains Eng.

According to Eng, it was an eye-opening study as it provided a BRAF inhibitor to patients as part of a clinical trial.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x